Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q4 2021 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了“资金或具有约束力的财务承诺先于公司将完成的工作到达公司”——即公司业务对手方在收到所购商品之前先支付现金、提前付款或锁定无论是否使用都必须支付的义务——并且管理层是否将这种预付款视为当前正在增长并为其下一阶段增长提供资金或降低风险的事物。 在电话会议中,管理层讨论了存款增长。Tom Casey提到:“During the quarter, we also grew our deposit base by 11% to $3.1 billion with average interest preparing deposit rates increasing to 38 basis points from 30 basis points as we grew our savings deposits by $304 million.” 存款是客户存入银行的资金,银行可以将其用于贷款。这可以视为客户提前将资金存入银行,银行随后将其用于放贷。但存款通常不是为特定服务或产品预付的款项,而是银行负债。然而,在银行背景下,存款是银行资金的重要来源,客户将资金存入银行,银行将其用于贷款。这类似于客户提前提供资金,但存款通常不是为特定交付物支付的,而是银行吸收的储蓄。管理层是否将其视为“提前资金”以资助增长?在电话会议中,管理层讨论了利用存款来资助贷款组合增长。例如,Scott提到:“we expect the impact of rising rates in 2022 to be muted. We anticipate that any increase in cost of funds on new deposits used to fund our balance sheet growth will be more than offset by the increased mix of high-yielding consumer loans.” 这表明存款用于资助资产负债表增长。但存款是银行常规业务,并非特定于“提前支付”的客户承诺。存款人将钱存入银行,银行支付利息,存款人可随时提取。这并非“支付-无论是否使用”的承诺,而是银行负债。然而,在更广泛的意义上,存款是客户提前将资金交给银行,银行随后将其用于贷款,但存款人并未购买特定服务,而是储蓄。因此,这可能不符合“提前支付”的定义,因为存款人并未为特定交付物付款,而是将资金委托给银行。 管理层是否提到其他形式的预付款?没有。他们提到了贷款发放,但那是银行发放贷款,不是客户预付。他们提到了存款增长,但存款是银行负债,不是客户为未来服务预付的款项。因此,没有迹象表明客户在收到服务前支付了款项。 此外,管理层没有提到任何“预付”或“提前支付”的客户承诺。他们讨论了贷款组合增长,但那是银行自己发放贷款,不是客户预付。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.